Astrazeneca Ab & Ors vs.p Kumar & Anr

Decided On : Aug-08-2019

Court : Delhi

LAW: Order 39 Rule 4, Order 39 Rule 1, the Patents Act, section 48, the Patents Act, section 64, the Indian Patent Act, section 107, Section 64, Section 64(1)(a, the Patents Act, Section 64(1, the Patents Act, Section 64(1)(h, Section 64(1)(j, Section 8, Section 64(1)(K, Section 3(d, the Patent Act, the Patent Act, Section 64(1, Section 64(1)(e, Section 64(1)(f, section 3(d, the Patent Act, section 8, section 2(1)(j, section 8, section 64, Section 8(1) & Section 8(2, Section 13(1)(b, Section 64(1)(a, Section 3(d, section 13(1)(a, the Patent Act, Section 8 of the Act, section 8, the Patent Act, IN229 31, Section 2(j, the Patent Act, Section 2(1, the Patents Act, ―invention‖, Section 4 of the Act, Section 20, the Atomic Energy Act, Section 3, Section 26(1, the Patents Act, IN229 47, Title 35, the Patent Act, Patents Act 61, the Patent Act, Section 3, Section 3(d, the Patent Act, the Patent Act, Section 3(d, Chapter II, Section 3(d, Section 3(d, Section 2(1, Section 2(1, Section 3(d, Section 3(d, Section 3(d, Section 3(d, Section 3(d, Section 3(d, Section 2(1, Section 3(d, the Patents Act, Section 3(d, Section 3(d, the Patent Act, IN229 72, Section 8, Section 8 and Section, section 8, section 8, Rule 12, Section 8, section 8, Section 8 of the Act, Section 8, Section 8(1, the Patents Act, Section 64(1)(m, Section 8 of the Act, Section 3(d, Section 64, the Patents Act, the Section 64, the Patents Act, Section 64(1)(f, Section 3(d, Section 64, the Patent Act

MONEY: ~J

DATE: + + +, 1023/2018, 1023/2018, 1023/2018 1, 1023/2018, 23.04.2018, 1023/2008, Claim 5, '907.7, the year 2005, 1970, 2015, six months, 2011, May 2012, October 2012, 57 11, the month of March 2018, the first week of April 2018, the first week of April 2018, the third week, April 2018, 57 13, 1023/2018, April 2018, 17.07.2018, Form 27, 14.07.2018, 2015, only 2017, 57, 22.07.1997, 2012, 2018, 1023/2018, 14.07.2018, 14.07.2018, 1970, 1020, 21, 57 23, 14.07.2018, October 2017, October 2015, 2009, 57 27, 1023/2018, 2013, 2nd February 1999, 1020, 32, 68, a year, 57 32, 2013, 1970, 1962‖, 2005, 1020, R2, 38, 2015, the section 64, 1970, 2015, 2009, Form 27, 21.03.2018, 57 44, 21.03.2018, the same period, 57 45, 2017, 57 46, the year 2017, the previous years, 2014, 6251910, '910, 2008, 2013, 2008, 54, years, 57 97, 57 55, Form 27, 24.06.2010, May 2011, October, 2012, 57, 2015, 57 64, efficacy;].‖ 65, 20-year, 57 3, 1970, the year 2005, 2005, 1998, 2005, 68, 17.10.2017, 2009, Form 3.75, 57 78, 2015, 80, 1970, 1970, the year 2005, 14.07.2018, quarterly, 2019

CARDINAL: 08.2019, 1, 57, three, 2, 22.03.2018, 23.04.2018, 2, 57, 18.07.2018, 984, 522.57, 1, 907, 3, 57 6, 1, two, 3, 25(2, No.2, two, 4.5-D, four, 4, 1-10, approximately 1, 3, more than 100, 5, No.2, No.2, 6, No.2, No.2, 7, 14.7.2018, 14.7.2018, 8, 57, No.2, 14.7.2018, 9, 10, 57, three, 11, 57, 2(1, 150, 1.5, 144, 134, 8, 150, 144, 134, 12, 57, 3, 13, 57, 14, 3(d, 15, 674, 1, 7, 27, 16, 57, No.2, two, two, 40, 17, No.2, 2, two, 18, 57, 6, 04.02.1999, two, 19, 68, 1.5, one, 20, 57, millions, 21, 57, 57, 55, 60, 27, 27, 22, 57, 6, 72,000/-, One, 23, 2(m, follows:-"―2, 1, 3, 20, at least one, 24, 57, 6, three, ―inventive, 34, 75, ―Inventive, 25, two, two, 1, 34, 26, 57, 26, 27, 27, 57, 29, 42, 1.5, one, 5, 150, 28, 57 229, 229, 5, one, 5, C1, C2-6, C1, C1, 29, 57, 5, one, 6, C1, two, 5, 6, one, two, two, one, 6, 1, C1, 4, 30, 57, 1, 7, 2, 2, 7, 4, 5, two, 64, 31, 57 40, 223, 157(2009, 12(2009, 3, 32, 57, 33, 34, 35, 36, 1,884,470, four, 1,797,194, four, four, three, 60, 90, 6,251,910, 910, 6,525,060, 060, 7,250,419, 37, 57, 7,265,124, 124, 8,425,934, 5, 15, 060, 419, 910, 38, 57, BRILINTA.50, 3, 265, 39, 57, 235, 235, 40, two, 100, 41, 134, 42, 57, 43, 57, 44, 27, 45, 57, 3(d, 46, at least one, 66, 47, 157, 48, 57, 169, 49, 57, 8.3.2000, 50, 57, 6,251,910, 10, 51, 57, 41, 1, 1, 1, 52, 57, 1, 57, 55, 60, 53, 225, 79, 54, 57, 82, 55, 57, 83, 1, 64, 1)(k, 56, 57, one, 57, 57

ORG: IAs.3986/2018 & 5096/2018, AB & ORS P KUMAR & ANR, IA No.4771/2018, ASTRAZENECA AB & ANR T RAO & ANR, ASTRA ZENECA AB & ANR, REDDYS LABORATORIES LIMITED, Advs, Adv, Adv, Adv, ―IN984, the Polymorph Patent, ―IN674, IA No.3986/2018, IA No.4771/2018, IA No.9332/2018, CPC, CPC, TICAGRELOR, IN907 IN984and IN674 4, IA No.3986/2018, TICAGRELOR, the CS(COMM.)749/2018 & etc, TICAGRELOR, TICAGRELOR, IN674 The, TICAGRELOR, TICAGRELOR, INN, IUPAC, TICAGRELOR, CS(COMM.)749/2018 & etc, TICAGRELOR, TICAGRELOR, TICAGRELOR, Micro Labs Limited, the Intellectual Property Appellate, Crystalline, Triazolo, TICAGRELOR, CS(COMM.)749/2018 & etc, Indian Patent, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, ACS, TICAGRELOR, BRILINTA, Rs.50/-, CS(COMM.)749/2018 & etc, Micro Labs Ltd, TICAGRELOR, BIGRELOR, the Intellectual Property Appellate Board, IPAB, Natco Pharma Ltd., TICAGRELOR, TICAGRELOR, ‗APIs, TICAGRELOR, TICAGRELOR, CS(COMM.)749/2018 & etc, Dr.Reddy‘s Laboratories Ltd., TICAGRELOR, TICAFLO, C&F Agents, TICAGRELOR, CS, Micro Labs Ltd., TICAGRELOR, BRILINTA, AXCER, Regulatory Agencies, Courts, TICAGRELOR, CS(COMM.)749/2018 & etc, No.241229, TICAGRELOR, TICAGRELOR, No.241229, TICAGRELOR, IN229, Reliance, BRILINTA, AXCER, USPTO, IN229, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, the Indian Drug Regulator, TICAGRELOR, TICAGRELOR, Reliance, Reliance, Reliance, TICAGRELOR, IN229and IN907, Reliance, CS(COMM.)749/2018 & etc, Reliance, Reliance, Controller, IA No.9332/2018, Dr.Reddy‘s Laboratories Ltd., TICAGRELOR, TICAGRELOR, TICAGRELOR, CS(COMM.)749/2018 & etc, Reliance, TICAGRELOR, IN229, TICAGRELOR, Markush, IN229, TICAFLO, TICAGRELOR, TICAGRELOR, BRILINTA, AXCER, CS(COMM.)749/2018 & etc, Natco Pharma Ltd., Indian Patent IN907 IN984and IN674, Reliance, Reliance, CS(COMM.)749/2018 & etc, the European Patent Office, Reliance, Reliance, Reliance, TICAGRELOR, Reliance, the Indian Patent Office, Reliance, CS(COMM.)749/2018 & etc, the Indian Patent Office, Reliance, TICAGRELOR, Reliance, Reliance, TICAGRELOR, Reliance, CS(COMM.)749/2018 & etc, Micro Labs Ltd., IN229 i.e. US910, TICAGRELOR, Reliance, Ever-Greening, TICAGRELOR, the Indian Patent Office, TICAGRELOR, IN907 IN984and IN674 Hence, CS(COMM.)749/2018 & etc, the European Patent Office Opposition Board, the Indian Patent Office, IPAB, Reliance, LA Roche Ltd., Cipla Ltd., Micro Labs Ltd., Micro Labs Ltd. CS(COMM.)749/2018 & etc, Natco Pharma Ltd., Natco Pharma Ltd., TICAGRELOR, TICAGRELOR, IN229 Working, BRILINTA, AXCER, TICAGRELOR, the India Patent Office, TICAGRELOR, TICAGRELOR, IN229, the Supreme Court, Novartis AG, CS(COMM.)749/2018 & etc, TICAGRELOR, IN229, TICAGRELOR, Reliance, the Supreme Court, Novartis AG, IN907, TICAGRELOR, TICAGRELOR, CS(COMM.)749/2018 & etc, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, CS(COMM.)749/2018 & etc, the US Laws, the Supreme Court, the Supreme Court, Imatinib Mesylate, TICAGRELOR, TICAGRELOR, IN229, TICAGRELOR, TICAGRELOR, CS(COMM.)749/2018 & etc, CS(COMM.)749/2018 & etc, the Supreme Court, Novartis AG, Union of India, the Supreme Court, ac, ―invention‖, CS(COMM.)749/2018 & etc, Supreme, Bishwanath Prasad Radhey Shyam, Hindustan Metal Industries, The Supreme Court, CS(COMM.)749/2018 & etc, Hindmarch on Patents, CS(COMM.)749/2018 & etc, 3rd Edn, Farbwrke Hoechst & B. Corporation, Untchan Laboratories, MNU, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, Dr. Reddy‘s Laboratories Ltd., TICAGRELOR, IN229, IN229:-"CS(COMM.)749/2018 & etc, NR9 R10, Hydroxyl Page 5, CH2CH2OH, CH2CH2OH, halogen, OR8, CS(COMM.)749/2018 & etc, halogen, groups and/or halogen, halogen, OR8, halogen, NR12R13, 8- cycloalkyl group, CS(COMM.)749/2018 & etc, Micro Labs Ltd., TICAGRELOR, NATCO Ltd., TICAGRELOR, TICAGRELOR, The Supreme Court, Biswnath Prasad Radhey Shyam, Hindustan Metal Industries, Bristol-Myers Squibb Company & Ors, TICAGRELOR, CS(COMM.)749/2018 & etc, Merck Sharp & Dohme Corporation & Anr, Glenmark Pharmaceuticals Ltd., Court, Court, Supreme Court, TICAGRELOR, the Statement of Working, the Controller of CS(COMM.)749/2018 & etc, TICAGRELOR, CS(COMM.)749/2018 & etc, IN229 IN907, BRILIANTA, Mylan INC, IN229, Mylan Inc., Mylan Pharmaceuticals Inc., Abbreviated New Drug Application, the U.S. Food and Drug Administration, FDA, AstraZeneca, AstraZeneca, the Approved Drug Products with Therapeutic Equivalence Evaluations, BRILINTA®, Plaintiff AstraZeneca UK Limited, AstraZeneca UK Limited, Notice Letters, TICAGRELOR, IN229 also.48, Micro Labs Ltd., the Orange Book of US FDA, Estonian Supplementary Protection Certificate, Canadian Patent Office Health Register, TICAGRELOR, IN229, TICAGRELOR, TICAGRELOR, TICAGRELOR, CS(COMM.)749/2018 & etc, Reddy’s Laboratories, Eli Lilly & Co.Ltd., the Royal Courts of Justice, Eli Lilly & Company Ltd., Apotex Pty Ltd., FCA214of Federal Court of, the Supreme Court of Canada, Apotex Inc., Sanofi-Synthelabo Canada Inc., Synthelabo & Minister of Health, Reddy’s Laboratories, Eli Lilly & Co., CS(COMM.)749/2018 & etc, Eli Lilly & Company Ltd., Apotex Pty Ltd.(supra, Eli Lilly, Apotex Inc., Sanofi-Synthelabo Canada Inc., Synthelabo &, CS(COMM.)749/2018 & etc, patent.‖ CS(COMM.)749/2018 & etc, the Supreme Court, Novartis, Union of India & Ors.(supra, the Supreme Court, the Supreme Court, the CS(COMM.)749/2018 & etc, the patent.‖ Hence, the Supreme Court, TICAGRELOR, TICAGRELOR, Mylan, TICAGRELOR, CS(COMM.)749/2018 & etc, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, TICAGRELOR, Cipla Ltd., Court, Court, CS(COMM.)749/2018 & etc, Court, TICAGRELOR, TICAGRELOR, TICAGRELOR, Micro Labs Ltd., IPAB, TICAGRELOR, CS(COMM.)749/2018 & etc, Dr.Reddy‘s Laboratories Ltd., TICAGRELOR, TICAGRELOR, Reliance, Dr. Reddy‘s Laboratories Ltd., TICAGRELOR, TICAGRELOR, IN229 CS(COMM.)749/2018 & etc, The CIPIH (Commission on Intellectual Property Rights Innovation and Public Health, the Supreme Court, Novartis, Union of India & Ors.(supra, the Supreme Court, Clauses, Clauses, CS(COMM.)749/2018 & etc, The New Oxford Dictionary, LA Roche Ltd., Cipla Ltd.(supra, Explanation, Erlotinib Hydrochloride, EP'226, CS(COMM.)749/2018 & etc, the American Court, Mylan INC, Reddy Laboratories Ltd., CS(COMM.)749/2018 & etc, Hardern, Hardern, AstraZeneca UK Limited, Hardern, the P2T-receptor.‖ 71, the Supreme Court, CS(COMM.)749/2018 & etc, China Patent, European Patent, the Patent Act.74, Co-Ordinate Bench, Chemtura Corporation v. Union of India & Ors, Controller, CS(COMM.)749/2018 & etc, The Co-Ordinate Bench, Bristol-Myers Squibb Company & Ors, Non Compliance of Section, Court, CS(COMM.)749/2018 & etc, CIPLA LTD, Court, Court, Court, the European Patent, Cipla Ltd., Court, the CS(COMM.)749/2018 & etc, ―vulnerable‖, Court, Court, Court, Co-Ordinate Bench, Bristol-Myers Squibb Company & Ors, CS(COMM.)749/2018 & etc, CS(COMM.)749/2018 & etc

PERSON: Pravin Anand, Archana Shankar, Devinder Rawat, Nishchal Anand, Sanchith Shivakumar, J.Sai Deepak, G.Nataraj, C.M.Lall, Rajeshwari, Sai Krishan, Gitanjali Mathew, Markush, R2, Pyrimidine Compound, IN984, IN229 Reliance, IN229, Fritz B. Blatter, WO283 Hence, IN229, IN229 Reliance, IN984, P.Kumar, P.Kumar, T. Rao, IN229 Reliance, IN229, IN229, Markush, Robert Riley, Reddy‘s Laboratory, Novartis, Fry L. J.in Humpherson v. Syer, Salmond L. J.in Rado v., John Tye & Son Ltd., Britannica, Vol, Vimadalal J.of Bombay High Court, IN229, Ticagrelor, Ticagrelor, Formula, Substituting, R4 Substituting Hydroxyethoxy, OCH2CH2OH, Formula, Page 4 - "Suitably R1, C3-8-cycloalkyl, R2, C3-8, C3-8-alkyl, Triazolo, TICAGRELOR, Bench, J.D.Joshi & Anr, Bench, Martin F.D’Souza v. Mohd, Consumer Fora, BRILINTA®, EWHC2345(Pat, Apotex, Markush, Andhyarujina, Subramanium, Hogan, IN229 Surprisingly, Formula, IN229, Robert Riley, Patents, Robert J.Riley, Rober J.Riley, Inhibition, Guile, Riley, IN229, Novartis, Riley, J.D.Joshi & Anr.(supra, xxxxxx xxx, J.D.Joshi & Anr.(supra

NORP: Indian, Indian, Indian, Indian, Crystalline, Indian, Indian, Indian, European, Chinese, European, IN984was, Korean, Chinese, ―invention‖, addressee, follows:-"―40, Rules, Paras

PRODUCT: IN907 IN984, R4, IN241229, IN229 Such, IN907, IN907 Chinese, R4, R4, C1-6 - OR8, C3, IN907, Appellant, Maj.(Retd, Single

GPE: IN674, IA, IA, TICAGRELOR, IN674, USA, BRILINTA, India, India, India, India, Sweden, China, India, China, South Korea, India, IN907is, IN229It, US, India, China, South Korea, India, India, India, US, US, USA, China, IN674, China, China, South Korea, Brazil, Argentina, India, China, China, US, India, Brilinta, USA, step‖, follows:-"―25, Halsbury, India, NO2, IN229, US, US, the United States, the District of Delaware, the United States, U.S., United Kingdom, London, United Kingdom, UK, US, IN229, Delaware, US, USA, US, US, US, UK, London, Australia, UK, compounds.‖, USA, IN229is, India, BRILINTA, Brilinta, F. Hoffmann-, USA, IN229, IN907and, India, US, US, USA, South Korea, China, India, India, India, China, China, F.HOFFMANN, China, F. Hoffmann-

WORK_OF_ART: R3, Prior Claiming of the defendant, IN229 For IN229, Mylan, Orange Book, the Orange Book Patents

ORDINAL: third, first, first, Firstly, First, Second

LOC: Europe, Europe, Europe, Europe

FAC: IN229, IN229, IN229, IN229, IN229, Stanhope Gate, IN229 Being

QUANTITY: No.1 as one, 3 - C1-4

EVENT: Form 27, Form 27

LANGUAGE: English